Intellia Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes
Ticker: NTLA · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1652130
Sentiment: neutral
Topics: corporate-governance, officer-appointment, director-departure, shareholder-vote
Related Tickers: NTLA
TL;DR
Intellia Therapeutics filed an 8-K detailing leadership changes and upcoming shareholder votes.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting events that occurred on June 11, 2025. The filing includes information regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Additionally, it covers the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This 8-K filing signals potential changes in corporate leadership and governance at Intellia Therapeutics, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially when combined with votes of security holders, can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- June 11, 2025 (date) — Earliest event reported
- June 12, 2025 (date) — Date of report
FAQ
What specific officer or director positions were affected by the reported departures or appointments?
The filing indicates "Departure of Directors or Certain Officers" and "Appointment of Certain Officers" but does not specify the names or exact positions in the provided text.
Were there any specific compensatory arrangements for officers detailed in this filing?
The filing mentions "Compensatory Arrangements of Certain Officers" as an item of information, but the details of these arrangements are not provided in the excerpt.
What matters were submitted to a vote of security holders?
The filing lists "Submission of Matters to a Vote of Security Holders" as an item, but the specific proposals or resolutions are not detailed in the provided text.
What financial statements or exhibits are included with this 8-K filing?
The filing states "Financial Statements and Exhibits" are included, but the specific content of these exhibits is not detailed in the excerpt.
What is the principal executive office address for Intellia Therapeutics, Inc.?
The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Intellia Therapeutics, Inc. (NTLA).